HOME >> BIOLOGY >> NEWS
Non-drug treatment for hypertension found effective in hard-to-control refractory hypertensives

Fort Lee, NJ -- June 30, 2003 Hard-to-control refractory hypertensives witnessed a significant blood pressure reduction when using a new non-drug treatment device, Resperate, according to a study published in this month's American Journal of Hypertension.

The 8-week study, performed at the WHO Collaborative Center for Prevention of CVD, the Barzilai Medical Center Ashkelon, Israel, demonstrated that 15-minutes daily self treatment with the Resperate device significantly reduced the blood pressure of patients who were not achieving goal blood pressure despite taking 3 or more antihypertensive drugs at maximum dosage.

The results of the American Journal of Hypertension study are consistent with outcomes reported in six previous peer-reviewed, published studies examining the effects of the device in the general uncontrolled hypertensive patient population and a recent mechanism-of-action review published in the American Heart Association's textbook, Hypertension Primer in May, 2003.

"These are evidence of the effectiveness of Resperate as an adjunctive treatment for hypertension" said Dr. Reuven Viskoper, the principal investigator and the past president of the Israeli Society of Hypertension. "The fact that this non-drug treatment delivered the same significant blood pressure reductions even in refractory hypertensives is clinically meaningful as it provides us with a much needed effective, and side-effect-free treatment option for this patient population".


'"/>

Contact: Tom Kirwan
tkirwan@intercure.com
201-720-7750 ext. 7136
InterCure
30-Jun-2003


Page: 1

Related biology news :

1. Leader in cancer treatment and prevention research honored
2. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
3. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
4. New treatment for fibromyalgia
5. The impact of genetic variations on the treatment of early rheumatoid arthritis
6. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
7. Early clinical treatment can halt progression of Alzheimers disease, UCI researchers find
8. Colleagues to recognize research leadership in cancer detection, prevention and treatment
9. New view of leukemia cells identifies best treatment options, Stanford researchers say
10. Genetic model for devastating form of paraplegia suggests new treatments
11. Protective mechanism exploited by tumors may provide new cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: